Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Abstract

The ability of nasally administered Lactobacillus rhamnosus CRL1505 to accelerate the recovery of respiratory B cell-mediated immunity against pneumococcal infection in replete malnourished mice was evaluated. Weaned mice were malnourished after consumption of a protein-free diet for 21 d. Malnourished mice were fed a balanced conventional diet (BCD) for 7 d (BCD group) or a BCD for 7 d with supplemental L. rhamnosus CRL1505 by the nasal route during the last 2 d (BCD+Lr group). Nonreplete malnourished and normal mice were used as the malnourished (MNC) and the well-nourished (WNC) control groups, respectively. Mice were challenged with Streptococcus pneumoniae at the end of each dietary treatment. The immune response was studied before the challenge and at different times postinfection. The MNC mice had less resistance to pneumococcal infection, fewer mature and immature B cells in lung and spleen, and a reduced production of specific antibodies compared with WNC mice. The BCD treatment did not induce a complete normalization of the number B cell populations and antibody amounts. However, the BCD+Lr group had normal numbers of spleen and lung B cells. Moreover, the BCD+Lr mice had a significantly lower susceptibility to S. pneumoniae infection and higher amounts of anti-pneumococcal antibodies. Although further studies are necessary to clarify the effect of malnutrition and nasally administered lactobacilli in other immune cell populations involved in the protection against respiratory pathogens, this work gives evidence of the importance of using nasal priming with probiotics to accelerate the recovery of respiratory immunity in immunocompromised malnourished hosts.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus rhamnosus CLR1505Enhanced Antibody ProductionBeneficial
Large
Lactobacillus rhamnosus CLR1505Enhanced Resistance to Streptococcus Pneumoniae InfectionBeneficial
Large
Lactobacillus rhamnosus CLR1505Improved Humoral ImmunityBeneficial
Large
Lactobacillus rhamnosus CLR1505Increased B Cell PopulationsBeneficial
Large
Lactobacillus rhamnosus CRL 1505Enhanced Antibody ProductionBeneficial
Large
Lactobacillus rhamnosus CRL 1505Improved Humoral ImmunityBeneficial
Large
Lactobacillus rhamnosus CRL 1505Increased B Cell PopulationsBeneficial
Large
Lactobacillus rhamnosus CRL 1505Reduced Susceptibility to InfectionBeneficial
Large
Lactobacillus rhamnosus LR04Accelerated Recovery of B Cell-Mediated Respiratory ImmunityBeneficial
Large
Lactobacillus rhamnosus LR04Increased Anti-Pneumococcal Antibody LevelsBeneficial
Large
Lactobacillus rhamnosus LR04Reduced Susceptibility to Pneumococcal InfectionBeneficial
Moderate
Lactobacillus rhamnosus LR05Improved ImmunityBeneficial
Large
Lactobacillus rhamnosus LR06Improved ImmunityBeneficial
Large
Lactobacillus rhamnosus LR06Increased B Cell CountBeneficial
Large
Lactobacillus rhamnosus LR06Increased Resistance to Pneumococcal InfectionsBeneficial
Large
Lactobacillus rhamnosus LR06Increased Specific Antibody ProductionBeneficial
Large
Lactobacillus rhamnosus LRa05Improved Humoral ImmunityBeneficial
Large
Lactobacillus rhamnosus LRa05Increased B Cell PopulationsBeneficial
Large
Lactobacillus rhamnosus LRa05Increased Specific Antibody ProductionBeneficial
Large
Lactobacillus rhamnosus LRa05Reduced Susceptibility to Pneumococcal InfectionBeneficial
Moderate
Back to top